Status:
COMPLETED
Social Stress and Suicide
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Past Major Depressive Episode
Euthymic
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Only vulnerable patients, when facing environmental stressors, attempt or commit suicide. Previous research demonstrated that suicide attempters usually misunderstand the social context and show impai...
Detailed Description
Hypothesis: 1. suicide attempters will have a lower cortisol, and, greater alpha-amylase and peripheral inflammatory response after a social stressor, compared to non-attempters 2. suicide attempters ...
Eligibility Criteria
Inclusion
- past major depressive episode according to the DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)
- euthymic (IDSC \< 14 and YMRS \< 7)
- ability to understand experimental procedures
- able to speak, read and understand French
- able to give written informed consent
- for suicide attempters only: Lifetime history of suicide attempt.
- for affective controls only: No lifetime history of suicide attempt
Exclusion
- Lifetime diagnosis of schizoaffective disorder, schizophrenia or social phobia throughout
- Menopause
- Alcohol or illicit substance use disorder in the last 6 months;
- Diagnosis of current cardiovascular (arrhythmia, hypertension, heart valve problems, past heart attack or stroke, congenital heart disease), respiratory (chronic obstructive pulmonary disease, asthma, cystic fibrosis, tuberculosis, lung tumor) endocrine (adrenal disorder, cushing syndrome, adrenal tumor, type-2 diabetes, androgen deficiency, congenital adrenal hyperplasia, hypogonadism, polycystic ovarian syndrome) or neurological disease (dementia, brain stroke, epilepsia, multiple sclerosis, huntington disease, muscular dystrophy, brain or spinal cord tumor, meningitis) based on the first interview, which can interfere with the cardiovascular, endocrine or neurocognitive outcomes of the study;
- current cardiovascular medication which directly affects heart or arterial function or corticoids intake; anticoagulants, antiplatelet agents and dual antiplatelet therapy, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, angiotensin-receptor neprilysin inhibitors, beta blockers, calcium channel blockers, vasodilators.
- Pregnancy (urine pregnancy test) or breastfeeding
- refusing to participate
- being in exclusion period for another study
- not being affiliated to the French National Social Security System
- having reached 4500€ annual compensation for participating to clinical trials
- being protected by law or deprived of liberty
Key Trial Info
Start Date :
January 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04714671
Start Date
January 27 2021
End Date
February 11 2025
Last Update
February 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Montpellier
Montpellier, Hérault, France, 34295